Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is a clinical-stage biotechnology company focused on therapies for immune-mediated and metabolic diseases, with a particular emphasis on ophthalmology and rare retinal conditions. News about Aldeyra often centers on the progress of its RASP (reactive aldehyde species) modulator platform and its late-stage product candidates reproxalap and ADX-2191.
Investors following ALDX news can expect regular updates on regulatory milestones, such as the U.S. Food and Drug Administration’s review of the New Drug Application for topical ocular reproxalap in dry eye disease, extensions of Prescription Drug User Fee Act (PDUFA) target action dates, and feedback on proposed labeling. Aldeyra also reports on orphan drug and fast track designations from the FDA and the European Medicines Agency for ADX-2191 in primary vitreoretinal lymphoma, retinitis pigmentosa, and related inherited retinal dystrophies.
The company’s news flow includes clinical trial readouts and pipeline updates, such as Phase 2 data for ADX-629 in alcohol-associated hepatitis, preclinical results for ADX-248 in models of central nervous system diseases associated with inflammation, and decisions to prioritize next-generation RASP modulators ADX-248 and ADX-246. Aldeyra also issues releases about Special Protocol Assessment agreements, manufacturing inspections and outcomes, and participation in healthcare and ophthalmology conferences and research and development webcasts.
This ALDX news page aggregates these company communications so readers can track developments in Aldeyra’s RASP platform, ophthalmic programs, and broader immune-mediated disease pipeline over time. For investors and observers, the news stream provides context on clinical progress, regulatory interactions, and strategic pipeline decisions that shape the company’s future prospects.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has priced a public offering of 10,000,000 shares at $12.50 per share, aiming to raise $125 million. The proceeds will fund preparations for a potential New Drug Application for its lead compound, reproxalap, and other corporate purposes. An additional 1,500,000 shares may be purchased by underwriters within 30 days. The offering is set to close around May 3, 2021, pending customary conditions. Jefferies and SVB Leerink are joint book-running managers, with other firms as co-lead managers.
Aldeyra Therapeutics (Nasdaq: ALDX) announced plans for a public offering of $125 million in common stock, with an option for underwriters to purchase an additional $18.75 million. The net proceeds will support a potential New Drug Application for reproxalap, its lead compound, and fund early pipeline development and general corporate purposes. Jefferies and SVB Leerink are the joint book-running managers for the offering, which is subject to market conditions. The offering is filed under an SEC registration statement effective from April 15, 2021.
Aldeyra Therapeutics (Nasdaq: ALDX) announced positive results from the Phase 3 INVIGORATE Trial for 0.25% reproxalap ophthalmic solution, targeting allergic conjunctivitis. The trial achieved statistical significance for primary and secondary endpoints, demonstrating a notable reduction in ocular itching and redness compared to vehicle. The findings suggest broad potential for reproxalap, pending FDA discussions later in 2021 regarding a New Drug Application. Reproxalap has shown consistent efficacy in over 1,200 patients across 14 trials, with no significant safety concerns reported.
Aldeyra Therapeutics (Nasdaq: ALDX) has announced a webcast and conference call for April 27, 2021, at 8:00 a.m. (ET) to discuss top-line results from the Phase 3 INVIGORATE Clinical Trial of reproxalap for treating allergic conjunctivitis. The event will offer insights into the clinical trial outcomes, which could influence future development strategies. Aldeyra's pipeline includes reproxalap for dry eye disease and ADX-2191 for proliferative vitreoretinopathy, emphasizing its focus on therapies for immune-mediated diseases.
Aldeyra Therapeutics (Nasdaq: ALDX) provided business updates and financial results for 2020. The company is advancing reproxalap in pivotal Phase 3 trials for dry eye disease and allergic conjunctivitis, vital markets in ophthalmology. Key highlights include completed enrollment in the INVIGORATE trial and finalized design of the TRANQUILITY trial. Aldeyra raised $74.7 million from an underwritten public offering, enhancing its financial position. The net loss for 2020 was $37.6 million, an improvement from $60.8 million in 2019, with R&D expenses significantly reduced.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that CEO Todd C. Brady, M.D., Ph.D. will discuss reproxalap as a novel treatment for dry eye disease at the Ophthalmology Innovation Summit’s Dry Eye Disease Innovation Showcase on March 11, 2021, from 1:00 p.m. to 4:00 p.m. ET. The virtual event features market overviews, company presentations, and expert panel discussions on the dry eye disease market. Registration is free. Aldeyra is focused on developing therapies for immune-mediated diseases and is conducting Phase 3 trials for reproxalap and other investigational compounds.
Aldeyra Therapeutics (Nasdaq: ALDX) will hold a conference call on March 11, 2021, at 8:00 a.m. ET to discuss its financial results for the year ending December 31, 2020, along with business highlights. Interested parties can join via dial-in or through a live webcast available on the company’s Investors & Media page. Aldeyra is a clinical-stage biotech company focused on developing therapies targeting immune-mediated diseases, with key compounds in clinical trials for conditions such as dry eye disease and COVID-19.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that President and CEO Todd C. Brady, M.D., Ph.D. will participate in fireside conversations at two upcoming conferences: the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET, and the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 9:20 a.m. ET. These events will be archived on the company's Investor & Media page for 90 days after the presentations. Aldeyra focuses on developing therapies for immune-mediated diseases.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that Todd C. Brady, M.D., Ph.D., President and CEO, will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 3:40 p.m. ET. A live webcast of the presentation will be available on their investor relations page, and it will remain archived for 90 days. Aldeyra is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases, with investigational compounds like reproxalap and ADX-629 targeting reactive aldehyde species.
Aldeyra Therapeutics (Nasdaq: ALDX) has finalized the Phase 3 TRANQUILITY Trial design for its 0.25% reproxalap ophthalmic solution aimed at treating dry eye disease. The primary endpoint is ocular redness improvement over 90 minutes in a dry eye chamber, with approximately 150 patients per arm. Results from the run-in cohort indicated a significant decline in tear RASP levels after reproxalap administration, confirming its mechanism of action. The TRANQUILITY and TRANQUILITY-2 trials are expected to begin in H1 2021, with results anticipated in the second half of the year.